| Year |
Citation |
Score |
| 2017 |
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, et al. Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016705640. PMID 28467729 DOI: 10.1200/JCO.2016.70.5640 |
0.332 |
|
| 2017 |
Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, ... ... Jones SE, et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016714147. PMID 28398846 DOI: 10.1200/JCO.2016.71.4147 |
0.344 |
|
| 2016 |
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. The New England Journal of Medicine. 375: 1925-1936. PMID 27959613 DOI: 10.1056/Nejmoa1607303 |
0.472 |
|
| 2015 |
O'Shaughnessy JA, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J, Krekow L, Holmes F, Vukelja S, Lindquist D, Sedlacek SM, Rivera R, Brooks R, McIntyre K, ... ... Jones S, et al. Patients with Slowly Proliferative Early Breast Cancer have Low 5-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26041745 DOI: 10.1158/1078-0432.CCR-15-0636 |
0.32 |
|
| 2013 |
Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Lindquist DL, Holmes FA, Allison MA, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. The Lancet. Oncology. 14: 1121-8. PMID 24007746 DOI: 10.1016/S1470-2045(13)70384-X |
0.357 |
|
| 2012 |
Jacquin JP, Jones S, Magné N, Chapelle C, Ellis P, Janni W, Mavroudis D, Martín M, Laporte S. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. Breast Cancer Research and Treatment. 134: 903-13. PMID 22270929 DOI: 10.1007/s10549-011-1933-0 |
0.354 |
|
| 2012 |
Hezewijk Mv, Hille ETM, Putter H, Rea D, Hasenburg A, Markopoulos C, Seynaeve C, Velde CJHvd, Jones SE. 391 Higher Risk of Locoregional Recurrences for Women Treated with Mastectomy Compared to Breast-Conserving Therapy in Postmenopausal Women with Early Breast Cancer Treated on the TEAM Trial European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70457-4 |
0.343 |
|
| 2012 |
Water Wvd, Bastiaannet E, Seynaeve C, Markopoulos C, Jones SE, Rea D, Hasenburg A, Putter H, Liefers GJ, Velde CJHvd. 22 Increased Breast Cancer Recurrence in Elderly Patients is Explained by a Higher Risk of Distant Recurrence – a TEAM Study Analysis European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70090-4 |
0.38 |
|
| 2012 |
Fontein D, Hadji P, Seynaeve C, Hasenburg A, Paridaens R, Vannetzel JM, Markopoulos C, Jones SE, Rea D, Velde CJHvd. 87. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors – A TEAM trial analysis Ejso. 38: 758-759. DOI: 10.1016/J.Ejso.2012.06.087 |
0.378 |
|
| 2011 |
Loesch D, Robert N, Jones S, Elkordy M, Ilegbodu D, Asmar L. Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study. Journal of Oncology Practice. 2: 268-73. PMID 20859353 DOI: 10.1200/JOP.2006.2.6.268 |
0.322 |
|
| 2011 |
Water Wvd, Hille ETM, Hadji P, Markopoulos C, Seynaeve C, Hasenburg A, Dirix L, Rea D, Jones SE, Velde CJHvd. 5158 POSTER Specific Adverse Events and Outcome in Hormone Receptor Positive Breast Cancer Patients on Endocrine Therapy – a TEAM Study Analysis European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71600-8 |
0.3 |
|
| 2011 |
Fontein DBY, Water Wvd, Bartlett JMS, Liefers GJ, Markopoulos C, Seynaeve C, Roumen RMH, Rea D, Jones SE, Velde CJHvd. 5017 POSTER DISCUSSION Efficacy of Endocrine Therapy Regimens in Major Histological Subtypes of Breast Cancer – a TEAM Study Analysis European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71459-9 |
0.366 |
|
| 2011 |
Markopoulos C, Water Wvd, Putter H, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, Velde CJHvd, Jones S. 5015 ORAL Age Specific Competing Mortality in Breast Cancer Patients -a TEAM Study Analysis European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)71457-5 |
0.355 |
|
| 2010 |
Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, et al. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2958-65. PMID 20479419 DOI: 10.1200/JCO.2009.24.1000 |
0.303 |
|
| 2010 |
Jones S, Putter H, Hasenburg A, Velde Cvd, Rea D, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Seynaeve C. Abstract PD08-03: Competing Causes of Mortality vs. Breast Cancer Mortality at 5-Years among 9766 Postmenopausal Women with Hormone Receptor Positive Early Breast Cancer Treated on the TEAM Study of Adjuvant Hormonal Therapy Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd08-03 |
0.371 |
|
| 2010 |
Hadji P, Asmar L, Nes Jv, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, Velde Cvd, Ziller M. Abstract P5-11-08: Effects of Exemestane or Tamoxifen on Bone Health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial: A Meta-Analysis Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P5-11-08 |
0.388 |
|
| 2010 |
Hasenburg A, Velde CJHvd, Seynaeve C, Rea DW, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Jones SE. 15 Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer Ejc Supplements. 8: 62. DOI: 10.1016/S1359-6349(10)70047-1 |
0.354 |
|
| 2009 |
Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1177-83. PMID 19204201 DOI: 10.1200/Jco.2008.18.4028 |
0.447 |
|
| 2009 |
Verma S, Mittmann N, Bernard L, Thompson M, Chan B, Asmar L, Jones S. Docetaxel plus cyclophosphamide is cost-effective compared to doxorubicin plus cyclophosphamide, based on an economic analysis of US oncology trial 9735: additional rationale to avoid anthracyclines in the adjuvant treatment of operable breast cancer?. Cancer Research. 69: 6105. DOI: 10.1158/0008-5472.Sabcs-6105 |
0.371 |
|
| 2009 |
Jones S, Seynaeve C, Hasenburg A, Rae D, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett J, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Research. 69: 15. DOI: 10.1158/0008-5472.Sabcs-15 |
0.389 |
|
| 2009 |
Rea D, Hasenburg A, Seynaeve C, Jones S, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Asmar L, Urbanski R, Velde Cvd, Bartlett J, Smeets J, et al. Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Cancer Research. 69: 11-11. DOI: 10.1158/0008-5472.Sabcs-09-11 |
0.432 |
|
| 2009 |
Velde Cvd, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, Markopoulos C, Smeets J, Nortier JWR, Jones SE. 2BA Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer Ejc Supplements. 7: 1. DOI: 10.1016/S1359-6349(09)72025-7 |
0.35 |
|
| 2009 |
Nes JGHv, Seynaeve C, Jones S, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Markopoulos C, Kranenbarg WMM, Velde CJHvd. 5139 Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries Ejc Supplements. 7: 301. DOI: 10.1016/S1359-6349(09)71031-6 |
0.366 |
|
| 2008 |
Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, Paridaens R, Jones S, Falcon S, Carpentieri M, Abbattista A, Lobelle JP. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1253-9. PMID 18323548 DOI: 10.1200/Jco.2007.13.3744 |
0.373 |
|
| 2008 |
Jones SE. Considerations in treatment choice for metastatic breast cancer. Breast Cancer (Tokyo, Japan). 15: 35-9. PMID 18224392 DOI: 10.1007/S12282-007-0005-0 |
0.451 |
|
| 2007 |
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 369: 559-70. PMID 17307102 DOI: 10.1016/S0140-6736(07)60200-1 |
0.433 |
|
| 2007 |
Crown JP, Burris HA, Jones S, Koch KM, Fittipaldo A, Parikh R, Koehler M. Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC) Journal of Clinical Oncology. 25: 1027-1027. DOI: 10.1200/Jco.2007.25.18_Suppl.1027 |
0.338 |
|
| 2007 |
Burris H, Crown JP, Jones S, Oliva C, Parikh ROMA, Stein S. 2109 POSTER Lapatinib in combination with Taxanes (T) – tolerability data in 484 patients with breast cancer (BC) Ejc Supplements. 5: 216. DOI: 10.1016/S1359-6349(07)70871-6 |
0.374 |
|
| 2006 |
Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5381-7. PMID 17135639 DOI: 10.1200/Jco.2006.06.5391 |
0.444 |
|
| 2006 |
Jones SE. Exemestane as adjuvant treatment of early breast cancer: Intergroup Exemestane Study/Tamoxifen Exemestane Adjuvant Multicenter trials Clinical Breast Cancer. 6. PMID 16595025 DOI: 10.3816/CBC.2006.s.002 |
0.317 |
|
| 2006 |
Coombes RC, Paridaens R, Jassem J, Velde CJVd, Delozier T, Jones SE, Hall E, Kilburn LS, Snowdon CF, Bliss JM. First mature analysis of the Intergroup Exemestane Study Journal of Clinical Oncology. 24. DOI: 10.1200/Jco.2006.24.18_Suppl.Lba527 |
0.389 |
|
| 2005 |
Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer Journal of Clinical Oncology. 23: 5542-5551. PMID 16110015 DOI: 10.1200/Jco.2005.02.027 |
0.462 |
|
| 2005 |
Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer Clinical Breast Cancer. 6. PMID 15865850 DOI: 10.3816/CBC.2005.s.009 |
0.305 |
|
| 2004 |
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. The New England Journal of Medicine. 350: 1081-92. PMID 15014181 DOI: 10.1056/Nejmoa040331 |
0.39 |
|
| 2004 |
Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, Smith DA, Stead A, Koch KM, Spector NL. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors Journal of Clinical Oncology. 22: 3179-3179. DOI: 10.1200/Jco.2004.22.90140.3179 |
0.331 |
|
| 2004 |
Versola M, Burris HA, Jones S, Wilding G, Taylor C, Pandite L, Smith DA, Stead A, Spector NL. Clinical activity of GW572016 in EGF10003 in patients with solid tumors Journal of Clinical Oncology. 22: 3047-3047. DOI: 10.1200/Jco.2004.22.90140.3047 |
0.393 |
|
| 2003 |
Jones SE. Fulvestrant: An Estrogen Receptor Antagonist That Downregulates the Estrogen Receptor Seminars in Oncology. 30: 14-20. PMID 14613022 |
0.323 |
|
| 2003 |
Ravdin P, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba W, Olsen S, Meyers ML, Jones S. 670 Phase III comparison of docetaxel (D)and pacilitaxel (P) in patients with metastatic breast cancer (MBC) Ejc Supplements. 1. DOI: 10.1016/S1359-6349(03)90701-4 |
0.377 |
|
| 2003 |
Burris H, LoRusso P, Jones S, McCormick J, Willcutt N, Hodge J, Bush P, Pandite L, Sabry J, Ho P. 570 A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors Ejc Supplements. 1. DOI: 10.1016/S1359-6349(03)90602-1 |
0.337 |
|
| 2002 |
Jones SE, Clark G, Koleszar S, Ethington G, Mennel R, Paulson S, Brooks B, Kerr R, Denham C, Savin M, Blum J, Kirby R, Stone M, Pippen J, George T, et al. Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer. Clinical Breast Cancer. 3: 147-52. PMID 12123539 DOI: 10.3816/CBC.2002.n.019 |
0.309 |
|
| 2002 |
O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2812-23. PMID 12065558 DOI: 10.1200/Jco.2002.09.002 |
0.45 |
|
| 2002 |
Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer Journal of Clinical Oncology. 20: 727-731. PMID 11821454 DOI: 10.1200/Jco.20.3.727 |
0.438 |
|
| 2000 |
Gale RP, Park RE, Dubois R, Bitran JD, Buzdar AU, Hortobagyi G, Jones SE, Lazar GS, Spitzer G, Swain SM, Vaughn CB, Vogel CE, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clinical Transplantation. 14: 32-41. PMID 10693633 DOI: 10.1034/J.1399-0012.2000.140107.X |
0.413 |
|
| 1999 |
Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, Roque T, Regan D, Schuster M, Dimitrov N, Garrison L, Lange M. Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer Journal of Clinical Oncology. 17: 3025-3032. PMID 10506596 DOI: 10.1200/Jco.1999.17.10.3025 |
0.418 |
|
| 1997 |
Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology. 15: 1318-1332. PMID 9193323 DOI: 10.1200/Jco.1997.15.4.1318 |
0.399 |
|
| 1996 |
Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 14: 2976-83. PMID 8918495 DOI: 10.1200/Jco.1996.14.11.2976 |
0.441 |
|
| 1995 |
Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 13: 2722-30. PMID 7595730 DOI: 10.1200/Jco.1995.13.11.2722 |
0.391 |
|
| 1995 |
Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, Jones SE, Bigley JW, Hohneker JA. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. Journal of Clinical Oncology. 13: 637-644. PMID 7533824 DOI: 10.1200/Jco.1995.13.3.637 |
0.445 |
|
| 1994 |
Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA, Fisher RI. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Annals of Internal Medicine. 120: 903-12. PMID 8172436 DOI: 10.7326/0003-4819-120-11-199406010-00002 |
0.403 |
|
| 1991 |
Mansfield CM, Fabian C, Dahlberg S, Jones S, Miller TP, Slyck EJb, Grozea P, Morrison F, Coltman CA, Fisher RI. Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease, A randomized Southwest Oncology study International Journal of Radiation Oncology Biology Physics. 21: 191. DOI: 10.1016/0360-3016(91)90571-K |
0.328 |
|
| 1989 |
Dana BW, Dahlberg S, Schnitzer B, Kjeldsberg CR, Jones SE, Carden J, Mundis R, Tranum BL. Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group Phase II trial Investigational New Drugs. 7: 247-250. PMID 2793382 DOI: 10.1007/Bf00170868 |
0.49 |
|
| 1988 |
Ahmann FR, Jones SE, Moon TE. The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. Journal of Surgical Oncology. 37: 116-122. PMID 3343839 DOI: 10.1002/Jso.2930370211 |
0.503 |
|
| 1987 |
Moon TE, Jones SE, Bonadonna G, Valagussa P, Powles T, Buzdar A, Montague E. Development and use of a natural history data base of breast cancer studies American Journal of Clinical Oncology: Cancer Clinical Trials. 10: 396-403. PMID 3310604 DOI: 10.1097/00000421-198710000-00006 |
0.448 |
|
| 1987 |
Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base American Journal of Clinical Oncology: Cancer Clinical Trials. 10: 387-395. PMID 3310603 DOI: 10.1097/00000421-198710000-00005 |
0.489 |
|
| 1987 |
Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL. Isotretinoin and Cutaneous Helper T-Cell Lymphoma (Mycosis Fungoides) Archives of Dermatology. 123: 201-204. DOI: 10.1001/Archderm.1987.01660260071016 |
0.43 |
|
| 1986 |
Miller TP, Cowan JD, Neilan BA, Jones SE. A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study. Cancer Chemotherapy and Pharmacology. 16: 67-9. PMID 3940222 DOI: 10.1007/Bf00255289 |
0.507 |
|
| 1986 |
Panettiere FJ, Jones SE, Oishi N, Eyre HJ, O'Bryan RM, Andes WA, Taylor SA, Grozea PN. Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study. Medical and Pediatric Oncology. 14: 78-80. PMID 3713640 DOI: 10.1002/Mpo.2950140204 |
0.352 |
|
| 1985 |
Gams RA, Bryan S, Dukart G, Weiss A, Case D, Jones S, Stein R. Mitoxantrone in malignant lymphoma Investigational New Drugs. 3: 219-222. PMID 4019123 DOI: 10.1007/Bf00174174 |
0.452 |
|
| 1985 |
Ahmann FR, Jones SE, Moon TE, Hammond N, Miller TP, Durie BGM. Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC). Cancer. 56: 730-737. PMID 4016669 DOI: 10.1002/1097-0142(19850815)56:4<730::Aid-Cncr2820560405>3.0.Co;2-E |
0.523 |
|
| 1985 |
Jones SE, Grozea PN, Miller TP, Slyck EJV, Balcerzak SP, Costanzi JJ, Morrison FS, Eyre HJ, Fabian CJ, Dabich L. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study. Journal of Clinical Oncology. 3: 1318-1324. PMID 3900301 DOI: 10.1200/Jco.1985.3.10.1318 |
0.43 |
|
| 1985 |
Grogan TM, Fielder K, Rangel C, Jolley CJ, Wirt DP, Hicks MJ, Miller TP, Brooks R, Greenberg B, Jones S. Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. American Journal of Clinical Pathology. 83: 279-288. PMID 2983525 DOI: 10.1093/Ajcp/83.3.279 |
0.302 |
|
| 1985 |
Kronland R, Grogan T, Spier C, Wirt D, Rangel C, Richter L, Durie B, Greenberg B, Miller T, Jones S. Immunotopographic assessment of lymphoid and plasma cell malignancies in the bone marrow. Human Pathology. 16: 1247-1254. PMID 2933317 DOI: 10.1016/S0046-8177(85)80038-1 |
0.343 |
|
| 1985 |
Barbour JS, Redding K, Beutler LE, Jones SE, Meyskens F. Psychosocial characteristics of cancer patients who choose laetrile therapy Journal of Psychosocial Oncology. 2: 93-108. DOI: 10.1300/J077V02N03_08 |
0.395 |
|
| 1984 |
Bethancourt B, Pond GD, Jones SE, Grogan T, Wasserman P. Mediastinal hematoma simulating recurrent hodgkin disease during systemic chemotherapy American Journal of Roentgenology. 142: 1119-1120. PMID 6609593 DOI: 10.2214/Ajr.142.6.1119 |
0.363 |
|
| 1984 |
Moon TE, Jones SE, Bonadonna G, Powles TJ, Rivkin S, Buzdar A, Montague E. Using a database of protocol studies to evaluate therapy: A breast cancer example Statistics in Medicine. 3: 333-339. PMID 6528133 DOI: 10.1002/Sim.4780030408 |
0.325 |
|
| 1984 |
Miller TP, Jones SE, Alberts DS, Mackel C. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas. Investigational New Drugs. 2: 75-77. PMID 6469502 DOI: 10.1007/Bf00173790 |
0.473 |
|
| 1984 |
Jones SE, Moon TE. The use of a natural history data base to compare outcome among several trials of adjuvant chemotherapy for stage II breast cancer Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 96: 148-154. PMID 6396768 DOI: 10.1007/978-3-642-82357-2_18 |
0.473 |
|
| 1984 |
Jones SE, Brooks RJ, Takasugi BJ, Garewal HS, Giordano GF, Ketchel SJ, Jackson R, Heusinkveld RS, Kemmer SR, Moon TE. Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984). Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrã¨S Dans Les Recherches Sur Le Cancer. 96: 133-40. PMID 6396766 DOI: 10.1007/978-3-642-82357-2_16 |
0.449 |
|
| 1984 |
Takasugi BJ, Robertone AB, Salmon SE, Jones SE, Alberts DS. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors Investigational New Drugs. 2: 387-390. PMID 6096287 DOI: 10.1007/Bf00171590 |
0.62 |
|
| 1983 |
Knight WA, Fabian C, Costanzi JJ, Jones SE, Coltman CA. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A Phase II trial of the Southwest Oncology Group. Investigational New Drugs. 1: 235-7. PMID 6678871 DOI: 10.1007/Bf00208895 |
0.418 |
|
| 1983 |
Knight WA, Von Hoff DD, Neidhart JA, Tranum BL, Fabian C, Jones SE. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group. Investigational New Drugs. 1: 181-4. PMID 6678866 DOI: 10.1007/Bf00172078 |
0.427 |
|
| 1983 |
Villar HV, Jones SE, Goodman GE, Grogan TM, Pond GD, Wangensteen SL. Posttreatment laparotomy for Hodgkin's disease. Archives of Surgery (Chicago, Ill. : 1960). 118: 1272-6. PMID 6639338 DOI: 10.1001/Archsurg.1983.01390110030008 |
0.469 |
|
| 1983 |
Garewal HS, Brooks RJ, Jones SE, Miller TP. Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1: 772-5. PMID 6422004 DOI: 10.1200/Jco.1983.1.12.772 |
0.425 |
|
| 1983 |
Jones SE, Haut A, Weick JK, Wilson HE, Grozea P, Fabian CJ, McKelvey E, Byrne GE, Hartsock R, Dixon DO, Coltman CA. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group Study. Cancer. 51: 1339-47. PMID 6186355 DOI: 10.1002/1097-0142(19830415)51:8<1339::Aid-Cncr2820510803>3.0.Co;2-8 |
0.466 |
|
| 1983 |
Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Talley R, Butler JJ, Byrne GE, Hartsock R, Dixon D, Salmon SE. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer. 51: 1083-90. PMID 6185212 DOI: 10.1002/1097-0142(19830315)51:6<1083::Aid-Cncr2820510619>3.0.Co;2-M |
0.681 |
|
| 1983 |
Kessler JF, Levine N, Meyskens FL, Lynch PJ, Jones SE. Treatment Of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) With 13-Cis-Retinoic Acid The Lancet. 321: 1345-1347. PMID 6134133 DOI: 10.1016/S0140-6736(83)92136-0 |
0.41 |
|
| 1983 |
Miller TP, Jones SE. Initial chemotherapy for clinically localized lymphomas of unfavorable histology Blood. 62: 413-418. DOI: 10.1182/Blood.V62.2.413.413 |
0.521 |
|
| 1982 |
Jones SE, Salmon SE, Allen H, Giordano GF, Davis S, Chase E, Moon TE, Heusinkveld RS. Adjuvant Treatment of Node-Positive Breast Cancer with Adriamycin-Cyclophosphamide with or Without Radiation Therapy: Interim Results of an Ongoing Clinical Trial Recent Results in Cancer Research. 80: 162-169. PMID 7036279 DOI: 10.1007/978-3-642-81685-7_27 |
0.49 |
|
| 1982 |
Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting Cancer Treatment Reviews. 9: 45-48. PMID 6299555 DOI: 10.1016/S0305-7372(82)80035-2 |
0.46 |
|
| 1982 |
Nathwani B, Dixon D, Jones S, Hartsock R, Rebuck J, Byrne GJ, Sheehan W, Kim H, Coltman CJ, Rappaport H. The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group Blood. 60: 1068-1074. DOI: 10.1182/Blood.V60.5.1068.1068 |
0.478 |
|
| 1981 |
Miller TP, Jones SE, Chester AB, Dorr RT. Phase II trial of vindesine in breast cancer, lymphoma and other tumors: future directions. Cancer Treatment Reviews. 81-6. PMID 7438127 DOI: 10.1016/S0305-7372(80)80013-2 |
0.367 |
|
| 1981 |
Nathwani BN, Diamond LW, Winberg CD, Kim H, Bearman RM, Glick JH, Jones SE, Gams RA, Nissen NI, Rappaport H. Lymphoblastic lymphoma: A clinicopathologic study of 95 patients Cancer. 48: 2347-2357. PMID 6895347 DOI: 10.1002/1097-0142(19811201)48:11<2347::Aid-Cncr2820481102>3.0.Co;2-X |
0.448 |
|
| 1981 |
Anderson TC, Jones SE, Soehnlen BJ, Moon TE, Griffith K, Stanley P. Immunocompetence and malignant lymphoma: immunologic status before therapy. Cancer. 48: 2702-2709. PMID 6458352 DOI: 10.1002/1097-0142(19811215)48:12<2702::Aid-Cncr2820481224>3.0.Co;2-L |
0.385 |
|
| 1980 |
Miller TP, Jones SE. Is there a role for radiotherapy in localized diffuse lymphomas? Cancer Chemotherapy and Pharmacology. 4: 67-70. PMID 6993038 DOI: 10.1007/Bf00254024 |
0.319 |
|
| 1980 |
Nash CH, Jones SE, Moon TE, Davis SL, Salmon SE. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer. 46: 2380-2388. PMID 6449280 DOI: 10.1002/1097-0142(19801201)46:11<2380::Aid-Cncr2820461113>3.0.Co;2-M |
0.627 |
|
| 1979 |
Rainey JM, Jones SE, Salmon SE. Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC) Cancer. 43: 66-71. PMID 761176 DOI: 10.1002/1097-0142(197901)43:1<66::Aid-Cncr2820430109>3.0.Co;2-1 |
0.663 |
|
| 1979 |
Herman TS, Hammond N, Jones SE, Butler JJ, Byrne GE, McKelvey EM. Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer. 43: 390-397. PMID 761173 DOI: 10.1002/1097-0142(197901)43:1<390::Aid-Cncr2820430155>3.0.Co;2-U |
0.506 |
|
| 1979 |
Dorr RT, Jones SE. Inapparent infiltrations associated with vindesine administration Medical and Pediatric Oncology. 6: 285-288. PMID 481319 DOI: 10.1002/Mpo.2950060403 |
0.358 |
|
| 1979 |
Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy New England Journal of Medicine. 300: 1295-1297. PMID 375088 DOI: 10.1056/Nejm197906073002302 |
0.447 |
|
| 1979 |
Salmon SE, Wendt A, Jones SE, Jackson R, Giordano G, Miller R, Heusinkveld R, Moon TE. Treatment of early breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: initial results of a brief and effective adjuvant program. Recent Results in Cancer Research. 68: 98-104. PMID 223207 DOI: 10.1007/978-3-642-81332-0_13 |
0.422 |
|
| 1979 |
Salmon SE, Jones SE. Studies of the combination of adriamycin and cyclophosphamide (Alone or with other agents) for the treatment of breast cancer Oncology (Switzerland). 36: 40-47. PMID 156337 DOI: 10.1159/000225316 |
0.659 |
|
| 1979 |
Lloyd RE, Jones SE, Salmon SE. Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer. 43: 60-65. PMID 153787 DOI: 10.1002/1097-0142(197901)43:1<60::Aid-Cncr2820430108>3.0.Co;2-M |
0.663 |
|
| 1979 |
Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Butler JJ, Byrne GE, Moon TE, Fisher R, Haskins CL, Coltman CA. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer. 43: 417-25. PMID 84706 DOI: 10.1002/1097-0142(197902)43:2<417::Aid-Cncr2820430203>3.0.Co;2-I |
0.499 |
|
| 1979 |
Persio EJD, Grozea PN, Fisher R, Jones SE, Coltman CA. Chemotherapy versus chemotherapy plus radiotherapy for stage IIIA, IIIB Hodgkin's disease. A southwest oncology group study International Journal of Radiation Oncology Biology Physics. 5: 138. DOI: 10.1016/0360-3016(79)90447-4 |
0.436 |
|
| 1978 |
Herman TS, Jones SE. Systematic restaging in patients with Hodgkin's disease. A Southwest Oncology Group study Cancer. 42: 1976-1982. PMID 709542 DOI: 10.1002/1097-0142(197810)42:4<1976::Aid-Cncr2820420442>3.0.Co;2-N |
0.476 |
|
| 1978 |
Hammond N, Jones SE, Salmon SE, Patton D, Woolfenden J. Predictive value of bone scans in an adjuvant breast cancer program. Cancer. 41: 138-142. PMID 626924 DOI: 10.1002/1097-0142(197801)41:1<138::Aid-Cncr2820410122>3.0.Co;2-6 |
0.635 |
|
| 1978 |
Meyskens FL, Jones SE. Terminal transferase: its evolving role New England Journal of Medicine. 298: 845-846. PMID 273144 DOI: 10.1056/Nejm197804132981510 |
0.421 |
|
| 1978 |
Brooks RJ, Jones SE, Gaines JA. Effects of BCG on peripheral blood counts and drug tolerance of patients with non-Hodgkin lymphoma receiving combination chemotherapy. Medical and Pediatric Oncology. 5: 1-7. PMID 85250 DOI: 10.1002/Mpo.2950050102 |
0.417 |
|
| 1978 |
Heusinkveld RS, Feen AE, Jones SE. Comprehensive radiotherapy for advanced Hodgkin's disease refractory to chemotherapy. Tumori. 64: 631-637. DOI: 10.1177/030089167806400610 |
0.507 |
|
| 1977 |
Aristizabal SA, Miller RC, Schlichtemeier AL, Jones SE, Boone ML. Adriamycin-irradiation cutaneous complications. International Journal of Radiation Oncology, Biology, Physics. 2: 325-31. PMID 863763 DOI: 10.1016/0360-3016(77)90091-8 |
0.336 |
|
| 1977 |
Goldman RL, Jones SE, Heusinkveld RS. Combination chemotherapy of metastatic malignant schwannoma with vincristine, adriamycin, cyclophosphamide, and imidazole carboxamide: a case report. Cancer. 39: 1955-1958. PMID 858125 DOI: 10.1002/1097-0142(197705)39:5<1955::Aid-Cncr2820390507>3.0.Co;2-F |
0.431 |
|
| 1977 |
Jones SE, Butler JJ, Byrne GE, Coltman CA, Moon TE. Histopathologic review of lymphoma cases from the Southwest Oncology Group. Cancer. 39: 1071-1076. PMID 334362 DOI: 10.1002/1097-0142(197703)39:3<1071::Aid-Cncr2820390310>3.0.Co;2-C |
0.384 |
|
| 1977 |
Jones SE. Radionuclides in oncology La Ricerca in Clinica E in Laboratorio. 7: 143-159. PMID 72399 DOI: 10.1007/Bf02879480 |
0.334 |
|
| 1977 |
Jones SE, Griffith K, Dombrowski P, Gaines JA. Immunodeficiency in patients with non-Hodgkin lymphomas. Blood. 49: 335-344. DOI: 10.1182/Blood.V49.3.335.335 |
0.467 |
|
| 1977 |
Heusinkveld RS, Feen AE, Jones SE. Comprehensive radiotherapy for advanced Hodgkin's disease refractory to chemotherapy International Journal of Radiation Oncology Biology Physics. 2: 52-53. DOI: 10.1016/0360-3016(77)90426-6 |
0.429 |
|
| 1976 |
Schechter JP, Jones SE, Woolfenden JM, Lilien DL, O'Mara RE. Bone scanning in lymphoma. Cancer. 38: 1142-1148. PMID 953962 DOI: 10.1002/1097-0142(197609)38:3<1142::Aid-Cncr2820380315>3.0.Co;2-K |
0.398 |
|
| 1976 |
McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma Cancer. 38: 1484-1493. PMID 791473 DOI: 10.1002/1097-0142(197610)38:4<1484::Aid-Cncr2820380407>3.0.Co;2-I |
0.532 |
|
| 1976 |
Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5‐FU vs. methyl‐CCNU plus bolus weekly 5‐FU. A southwest oncology group study Cancer. 38: 1-7. PMID 779949 DOI: 10.1002/1097-0142(197607)38:1<1::Aid-Cncr2820380102>3.0.Co;2-S |
0.37 |
|
| 1976 |
Jones SE, Salmon SE. The role of radionuclides in clinical oncology Seminars in Nuclear Medicine. 6: 331-346. PMID 62399 DOI: 10.1016/S0001-2998(76)80012-8 |
0.57 |
|
| 1975 |
Jones SE, Durie BGM, Salmon SE. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer. 36: 90-97. PMID 1203853 DOI: 10.1002/1097-0142(197507)36:1<90::Aid-Cncr2820360104>3.0.Co;2-H |
0.68 |
|
| 1975 |
McMahon LJ, Jones SE, Durie BGM, Salmon SE. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma Cancer Letters. 1: 97-101. PMID 65213 DOI: 10.1016/S0304-3835(75)95630-X |
0.638 |
|
| 1975 |
Jones SE, Lilien DL, O'Mara RE, Durie BGM, Salmon SE. Indium-111 bleomycin tumor scanning in lymphoma. Medical and Pediatric Oncology. 1: 11-21. PMID 60694 DOI: 10.1002/Mpo.2950010104 |
0.407 |
|
| 1975 |
Lilien DL, Jones SE, O'Mara RE, Salmon SE, Durie BGM. A clinical evaluation of indium-111 bleomycin as a tumor-imaging agent. Cancer. 35: 1036-1049. PMID 46776 DOI: 10.1002/1097-0142(197504)35:4<1036::Aid-Cncr2820350405>3.0.Co;2-2 |
0.581 |
|
| 1973 |
Jones SE, Durie BGM, Salmon SE. Immunologic Aspects of the Hematologic Neoplasms Postgraduate Medicine. 54: 209-216. PMID 27393023 DOI: 10.1080/00325481.1973.11713622 |
0.55 |
|
| 1973 |
Moore MR, Jones SE, Bull JM, William LA, Rosenberg SA. MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients Cancer. 32: 52-60. PMID 4716784 DOI: 10.1002/1097-0142(197307)32:1<52::Aid-Cncr2820320107>3.0.Co;2-S |
0.678 |
|
| 1973 |
Jones SE, Fuks Z, Kaplan HS, Rosenberg SA. Non-Hodgkin's lymphomas. V. Results of radiotherapy. Cancer. 32: 682-691. PMID 4580229 DOI: 10.1002/1097-0142(197309)32:3<682::Aid-Cncr2820320322>3.0.Co;2-M |
0.736 |
|
| 1973 |
Jones SE, Fuks Z, Bull M, Kadin ME, Dorfman RF, Kaplan HS, Rosenberg SA, Kim H. Non‐hodgkin's lymphomas iv. clinicopathologic correlation in 405 cases Cancer. 31: 806-823. PMID 4574662 DOI: 10.1002/1097-0142(197304)31:4<806::Aid-Cncr2820310408>3.0.Co;2-1 |
0.714 |
|
| 1973 |
Jones SE. Autoimmune disorders and malignant lymphoma Cancer. 31: 1092-1098. PMID 4574456 DOI: 10.1002/1097-0142(197305)31:5<1092::Aid-Cncr2820310509>3.0.Co;2-B |
0.413 |
|
| 1972 |
Moore MR, Bull JM, Jones SE, Rosenberg SA, Kaplan HS. Sequential Radiotherapy and Chemotherapy in the Treatment of Hodgkin's Disease: A Progress Report Annals of Internal Medicine. 77: 1-9. PMID 5052446 DOI: 10.7326/0003-4819-77-1-1 |
0.693 |
|
| 1972 |
Jones SE, Rosenberg SA, Kaplan HS. Non-Hodgkin's lymphomas. I. Bone marrow involvement. Cancer. 29: 954-960. PMID 5017364 DOI: 10.1002/1097-0142(197204)29:4<954::Aid-Cncr2820290442>3.0.Co;2-5 |
0.687 |
|
| 1972 |
Jones SE, Moore M, Blank N, Castellino RA. Hypersensitivity to procarbazine (Matulane®) manifested by fever and pleuropulmonary reaction Cancer. 29: 498-500. PMID 5013552 DOI: 10.1002/1097-0142(197202)29:2<498::Aid-Cncr2820290240>3.0.Co;2-O |
0.358 |
|
| 1972 |
Rosenberg SA, Moore MR, Bull JMC, Jones SE, Kaplan HS. Combination chemotherapy and radiotherapy for Hodgkin's disease Cancer. 30: 1505-1510. PMID 4641759 DOI: 10.1002/1097-0142(197212)30:6<1505::Aid-Cncr2820300614>3.0.Co;2-L |
0.694 |
|
| 1972 |
Jones SE, Rosenberg SA, Kaplan HS, Kadin ME, Dorfman RF. Non-Hodgkin's lymphomas. II. Single agent chemotherapy. Cancer. 30: 31-38. PMID 4557278 DOI: 10.1002/1097-0142(197207)30:1<31::Aid-Cncr2820300106>3.0.Co;2-A |
0.735 |
|
| 1972 |
Jones SE, Kaplan HS, Rosenberg SA. Non-Hodgkin's Lymphomas Radiology. 103: 657-662. PMID 4553978 DOI: 10.1148/103.3.657 |
0.731 |
|
| Show low-probability matches. |